Emerging Targeted Therapy for Bladder Cancer
Constance Thibault1, Yohann Loriot2
1Medical Oncology Department, European Georges Pompidou Hospital, APHP.5, 20 rue Leblanc, Paris 75015, France.
Abstract:
For the last decade, biology of urothelial tumorigenesis has been widely explored, helping to better understand the molecular pathways in urothelial carcinoma (UC). Until recently, no targeted therapies have been approved in UC. However, several new molecules have shown promising results in metastatic UC: fibroblast growth factor receptor inhibitors, conjugated antibodies, PARP inhibitors, and antiangiogenics. In this article, the authors review the targeted therapies that are being evaluated in bladder UC.
Insights
Targeted therapies are revolutionizing urothelial carcinoma (UC) treatment. This review explores promising new drugs like FGFR inhibitors and antibody-drug conjugates for metastatic UC.
Area of Science:
- Oncology
- Urothelial Carcinoma Biology
- Molecular Pathways
Background:
- Urothelial carcinoma (UC) has seen extensive research into its tumorigenesis over the past decade.
- Historically, UC lacked approved targeted therapies.
- Recent advancements have introduced novel therapeutic strategies.
Purpose of the Study:
- To review the current landscape of targeted therapies for bladder urothelial carcinoma.
- To highlight emerging molecular pathways and their therapeutic implications.
Main Methods:
- Literature review of targeted therapies in bladder UC.
- Analysis of clinical trial data for novel agents.
- Synthesis of information on fibroblast growth factor receptor inhibitors, conjugated antibodies, PARP inhibitors, and antiangiogenics.
Main Results:
- Several targeted therapies demonstrate significant promise in metastatic UC.
- Fibroblast growth factor receptor (FGFR) inhibitors show efficacy.
- Conjugated antibodies, PARP inhibitors, and antiangiogenics are also under evaluation.
Conclusions:
- Targeted therapies represent a new frontier in managing advanced urothelial carcinoma.
- Ongoing research is crucial for developing effective treatments for UC.
- The reviewed agents offer hope for improved patient outcomes in metastatic settings.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...